Relay Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $3.47B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $3.00M | $-0.41 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | After market close | $7.00M | $-0.32 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | $-0.43 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $700.00K | $-0.41 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 5, 2025 | After market close | $7.70M | $-0.46 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | After market close | – | $-0.45 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $0 | $-0.63 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 22, 2024 | After market close | – | – | – |
Press releases
Announcements Relay Therapeutics filed with the SEC
AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT
Material agreement · Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Material agreement · Results of operations · EX-99.2 to Form 8-K
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vascular Anomalies Update May 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zovegalisib Triplet Disclosure April 2026 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
J.P. Morgan Conference Presentation January 2025 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
2024 SABCS – RLY-2608 Data Update December 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Announces Proposed Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RLY-2608 Data September 9, 2024 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Combination with RLY-2608
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Relay Therapeutics Discloses Three New Programs at New Program & Platform Event
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
New Program & Platform Event June 2024 Exhibit 99.3
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
J.P. Morgan Conference Presentation January 2024 Exhibit 99.1
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Relay Therapeutics Announces $30 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RLY-4008 (lirafugratinib) in FGFR2-Altered Solid Tumors October 2023 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation As of August 08, 2023 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
Regulation FD disclosure · EX-99.1 to Form 8-K
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
Results of operations · EX-99 to Form 8-K
RLY-2608 Initial Clinical Data Presentation at AACR Annual Meeting April 2023 Exhibit 99.1
Regulation FD disclosure · Other events · EX-99 to Form 8-K
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
Regulation FD disclosure · Other events · EX-99#2 to Form 8-K
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
Results of operations · EX-99 to Form 8-K